Influence of chronic Pseudomonas aeruginosa infection on airway inflammation during respiratory viral infections in adults with cystic fibrosis (CHRONOVIR)

Influence of chronic Pseudomonas aeruginosa infection on airway inflammation during respiratory viral infections in adults with cystic fibrosis (CHRONOVIR) - CHRONOVIR

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00026774

Enrollment

Registered

2021-10-19

Start date

2021-10-04

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E84

Interventions

Group 1: Pseudomonas aeruginosa positive patients. A total of 30 patients will participate in the study, 15 of them with chronic Pseudomonas aeruginosa infection and 15 Pseudomonas-negative individua

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Age = 18 years. - Confirmed diagnosis of CF by genetic testing. - Regular patient of the Christiane Herzog CF Center Frankfurt with data from at least two routine check-ups and one annual check-up in the 12 months prior to inclusion in the study. - PA free OR chronic pulmonary infection with PA. - Written informed consent.

Exclusion criteria

Exclusion criteria: - Z.n. lung transplantation. - Life expectancy < 6 months or listed for lung transplantation. - Systemic steroid therapy. - Intravenous antibiotic therapy in the last 4 weeks. - Last pulmonary infection exacerbation (clinical definition: indication for anti-infective therapy (oral/intravenous). - Intermittent PA infection - Other chronic disease or infection with pulmonary infection not associated with CF (such as tuberculosis, lung carcinoma). - Pregnancy - Known alcohol or drug abuse.

Design outcomes

Primary

Measure	Time frame
Change in local and systemic inflammatory markers (differential blood count, C-reactive protein, concentration of pro-inflammatory cytokines and chemokines including IL-6, IL-1ß, CXCL-8, CXCL-10) in sputum and serum in patients with and without chronic PA infection.	—

Secondary

Measure	Time frame
- Number of positive viral detections in patients with and without chronic PA infection. - Number of exacerbations in patients with and without chronic PA infection during the observation period (prospective) and in the past 12 months before inclusion. - Pulmonary Functional Progression (FEV-1). - Transcriptome/gene expression analyses (Paxgene).	—

Countries

Germany

Contacts

Public ContactGernot Rohde

Universitätsklinikum Frankfurt am MainMedizinische Klinik 1Schwerpunkt Pneumologie

Pneumo.Studien@kgu.de069 6301 6336

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026